As diabetes management develops toward precision, continuity and digitalization, continuous glucose monitoring (CGM) systems have become one of the most popular product categories in the medical device sector. The National Medical Products Administration has issued the technical review guidelines for CGM registration, among which the revised 2023 edition is listed in the current catalogue of medical device registration review guidelines. A number of CGM products have also been approved for marketing via the 510(k) pathway according to FDA database records.
For registration applicants, developers and project teams, the challenges of such products lie not merely in the application phase, but in whether product definition, performance verification, software documentation, data compliance and clinical route preparation can be completed in line with medical device registration requirements from the early R&D stage. Delaying these tasks will likely trigger concentrated defects at the registration stage, resulting in supplementary data requests, rework and out-of-control project timelines.
In practice, most CGM projects prioritize prototype development, algorithm performance and market schedule at the preliminary stage. Yet when shifting to registration preparation, developers are confronted with undefined product scope, incomplete evidence chains, insufficient software documentation and delayed initiation of clinical trials. Typical drawbacks cited in original documents including improper registration unit division, defective clinical trial design, non-compliance of software verification with IEC 62304, and inadequate planning for AI algorithm interpretability and data compliance are not isolated errors but consequences of inadequate upfront planning.
This distinguishes continuous glucose monitoring systems from ordinary single-component devices. A typical CGM consists of disposable sensors, transmitters, receivers or mobile applications as well as software for data processing. Separate development of these components makes it difficult to build consistent argumentation for registration submission, risk analysis and clinical evaluation afterward.
A common misconception
"Complete product development prior to registration planning." Such an approach concentrates regulatory risks to later phases for CGM products and eventually leads to higher costs for supplementary submission and rework.
Whether a continuous glucose monitoring system project can progress smoothly hinges first on proper product definition rather than immediate compilation of application documents. As specified in reference documents, registration unit classification shall be comprehensively determined by technical principles, structural composition, performance indicators and intended use. Sensors differing in wear duration, calibration modes or reaction principles generally cannot be categorized into a single registration unit.
In terms of project management, product portfolio planning should be finalized upon project initiation instead of deciding on grouping for submission right before product testing. Failure to align registration unit division with product roadmap in advance tends to result in redundant documents, repeated tests and forced adjustments to registration routes. For applicants, well-defined product scope improves registration efficiency and ensures preclinical and clinical evidence is developed consistently around unified product specifications.
Competition among CGM projects appears to center on product performance, yet essentially lies in the efficiency of evidence chain arrangement. The source document specifies that accuracy indicators, in-use stability, warm-up time, anti-interference performance, biocompatibility and material selection shall all be arranged at the early R&D phase, with special emphasis on MARD, interfering substances including vitamin C and acetaminophen, biocompatibility testing and toxicology assessment for new materials.
Accordingly, performance verification shall not be completed in a rush shortly before registration submission. A more reliable solution is to build a closed loop of "performance data – risk assessment – verification protocol – archived documents" progressively during the prototype development phase. Mutually supportive results from in vitro tests, animal trials, material assessments and core performance parameters help construct robust demonstration logic for subsequent registration and technical review.
Material selection at this stage goes beyond technical realization. The recommendation to prioritize medical-grade materials with proven history in medical devices essentially reminds the project team that aggressive material selection generally increases the complexity of biological evaluation and raises overall project uncertainties.
For continuous glucose monitoring systems, software directly determines product operation logic, data display and clinical interpretability. Key concerns specified in source documents include IEC 62304 software lifecycle requirements, algorithm interpretability, representativeness of training datasets, data encryption and anti-tampering measures. Hence, embedded software, mobile applications and trend-prediction-related algorithm functions shall never be treated as auxiliary modules developed after hardware finalization.
In practice, many teams start drafting requirement specifications, architectural designs, verification protocols and traceability records only after hardware prototypes are nearly finalized. Though seemingly time-saving in early development, this approach disconnects documentation from actual development, results in incomplete verification closure and insufficient supporting documents for risk control. For software-based medical devices or AI-equipped CGM products, such deficiencies will substantially raise communication costs during subsequent regulatory review.
Key Reminder
Hardware performance is rarely underestimated in CGM projects; instead, major overlooked risks stem from inconsistent documentation, inadequate data security arrangements and flawed algorithm justification against real development activities.
Source documents identify early planning of clinical evaluation pathways as a critical preliminary task during R&D, advising teams to address statistical specifications, sample design and coverage of hypoglycemic and hyperglycemic ranges well in advance. For most CGM programs, the core challenge is not whether clinical trials are required, but when to finalize the clinical pathway and what evidentiary logic will back subsequent registration.
Disconnect between prototype development, performance verification and clinical protocol design commonly leads to mismatched eligibility criteria, endpoint definitions, statistical planning and site coordination. Far from being the final registration step, clinical protocols serve as an essential early roadmap for CGM development.
Developers are advised to align clinical pathway design with preliminary performance data, defined software scope and intended target populations. This ensures clinical trials, data management and biostatistical activities evolve as an integrated extension of the overall registration evidence chain rather than disjointed standalone tasks.
Although CGM belongs to a segmented product category, it sets stringent requirements on project management capabilities. Separate and isolated progress across hardware performance, consumable materials, software documentation, cybersecurity, clinical protocols, registration application and quality system inevitably triggers extensive rework in later development stages.
From the perspective of practical project services, this is where CGM projects are most in need of professional assistance. Valuable medical device CRO service goes beyond drafting individual documents; it integrates product definition, clinical evaluation, clinical trials, software compliance and dossier compilation into one actionable roadmap to enable early risk identification midway through R&D.
From R&D to registration of continuous glucose monitoring systems, the core difficulty never lies merely in the completeness of application documents, but in whether product scope, performance evidence, software documentation and clinical pathways are established in accordance with regulatory logic during the R&D phase. Sufficient early emphasis on product definition and evidence chain management helps reduce supplementary data requests, cut communication costs and achieve better overall project controllability.
For parties engaged in CGM development, medical device registration or clinical preparation, a prudent strategy avoids the "develop first, register later" mindset and integrates R&D, clinical work, registration and quality management into a unified project roadmap. Deda Medical provides customized support covering preliminary registration strategy formulation, evidence planning, software compliance sorting and dossier preparation based on specific product configurations and project progress. Final assessments are recommended to be further confirmed against the latest official regulatory documents and practical project conditions.
